VARIED DOSES OF TRIVALENT INFLUENZA BY JET INJECTOR

通过喷射注射器注射不同剂量的三价流感

• 批准号: 6263561
• 负责人: LISA JACKSON
• 金额: $ 0.39万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263561
• 关键词: biomedical equipment; biomedical equipment safety; clinical research; clinical trial phase I; dosage; human subject; immunization; influenza vaccines; injection /infusion; technology /technique development

Administration of vaccines by jet injector (JI) offers several potential advantages over the traditional needle and syringe (N&S) administration of immunizations. The first is potentially improved immunogenicity, which may allow for lower doses of vaccine to be administered. This may reduce the cost per dose of vaccine or allow for a higher dose yield with current production methods. Second, JI administration may be associated with a more rapid rise in antibody titer, resulting in a more immediate conference of protection following vaccination. The third is a reduction of the risk of transmission of blood borne pathogens resulting from improper sterilization of N&S's and inadequate disposal of sharps in developing countries. Lastly, JI administration may be less painful than N&S administration. In this study, healthy adults will be vaccinated with varyng doses of influenza vaccine, by JI and N&S. If adminstration by JI is associated with advantages in terms of tolerability, immunogenicity, or kinetics of antibody rise, this will support further efforts to develop and test JI devices in both adult and pediatric populations.

通过喷射注射器（JI）施用疫苗提供了优于传统针和注射器（N&S）施用免疫的几个潜在优点。 第一个是潜在地改善免疫原性，这可能允许施用较低剂量的疫苗。 这可能会降低每剂疫苗的成本，或者使用当前的生产方法可以获得更高的剂量产量。 第二，JI管理可能与抗体滴度的更快上升有关，导致疫苗接种后更直接的保护作用。 第三是减少发展中国家因N&S消毒不当和锐器处置不当而造成的血液传播病原体的风险。 最后，联合执行管理可能比N&S管理更少痛苦。 在这项研究中，健康成人将接种不同剂量的流感疫苗，由JI和N&S。 如果JI给药在耐受性、免疫原性或抗体上升动力学方面具有优势，这将支持进一步努力在成人和儿童人群中开发和测试JI器械。